Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutetium-177-PSMA in oligometastatic hormone-sensitive prostate cancer
NL-OMON59605Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Jul 2020
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa) (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Fraction of patients with disease progression within 6 months and Time to disease progression and meeting EOT 1 criteria. Started Jul 2020; status: completed.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON59605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59605.